J. Goldman & CO LP Rigel Pharmaceuticals Inc Transaction History

J. Goldman & CO LP

$3.21 Billion
Q3 2024

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$1.1 - $12.2 $148,500 - $1.65 Million	-135,000 Reduced 81.9%	29,839 $35,000
Q2 2022 Aug 15, 2022	SELL	$0.67 - $3.19 $244,594 - $1.16 Million	-365,066 Reduced 68.89%	164,839 $186,000
Q1 2022 May 16, 2022	BUY	$2.22 - $3.45 $750,506 - $1.17 Million	338,066 Added 176.22%	529,905 $1.58 Million
Q4 2021 Feb 14, 2022	BUY	$2.36 - $3.57 $286,740 - $433,755	121,500 Added 172.73%	191,839 $508,000
Q3 2021 Nov 15, 2021	SELL	$3.5 - $4.5 $868,409 - $1.12 Million	-248,117 Reduced 77.91%	70,339 $255,000
Q2 2021 Aug 16, 2021	BUY	$3.09 - $4.54 $835,001 - $1.23 Million	270,227 Added 560.3%	318,456 $1.38 Million
Q1 2021 May 17, 2021	SELL	$3.35 - $4.93 $176,913 - $260,353	-52,810 Reduced 52.27%	48,229 $165,000
Q4 2020 Feb 16, 2021	SELL	$2.35 - $3.74 $1.74 Million - $2.77 Million	-741,447 Reduced 88.01%	101,039 $354,000
Q3 2020 Nov 16, 2020	SELL	$1.78 - $4.13 $328,516 - $762,232	-184,560 Reduced 17.97%	842,486 $2.02 Million
Q2 2020 Aug 14, 2020	BUY	$1.41 - $2.05 $1.04 Million - $1.5 Million	734,047 Added 250.53%	1,027,046 $1.88 Million
Q1 2020 May 15, 2020	BUY	$1.27 - $3.0 $372,108 - $878,997	292,999 New	292,999 $457,000
Q2 2018 Aug 14, 2018	SELL	$2.83 - $4.11 $2.36 Million - $3.42 Million	-832,500 Closed	0 $0
Q1 2018 May 15, 2018	SELL	$3.54 - $4.54 $546,930 - $701,430	-154,500 Reduced 15.65%	832,500 $2.95 Million
Q4 2017 Feb 14, 2018	BUY	$3.23 - $4.3 $167,960 - $223,600	52,000 Added 5.56%	987,000 $3.83 Million
Q3 2017 Nov 14, 2017	BUY	$2.18 - $2.57 $2.04 Million - $2.4 Million	935,000	935,000 $2.38 Million

Others Institutions Holding RIGL

# of Institutions

Shares Held

334K

Call Options Held

Put Options Held

View Full List

About RIGEL PHARMACEUTICALS INC

Ticker RIGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 172,836,000
Market Cap $2.96B
Description
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is ...

More about RIGL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of J. Goldman & CO LP, based on Form 13F filings with the SEC.

News

Stay updated on J. Goldman & CO LP with notifications on news.

Account